Want real case studies? 10 seconds to sign up
Join the platform
Vetted consultants
How we vet consultants
Only firms that pass our review are listed here.
- We assess regulatory experience, service scope, and professional credentials.
- Approved status may be revoked if standards are not maintained.
December 15, 2025
Approximately 5 minutes
Reviewed by Nate Lam, Founder & Director, ElendiLabs
China's Dual Drug Pricing System: CDR Registration to Support Global Expansion
China is implementing a transformative approach to pharmaceutical pricing with the introduction of the China Drug Registry (CDR). This database serves as a formal record of transaction prices occurring outside the public health insurance system, specifically in private hospitals, online platforms, retail pharmacies, and high-end medical institutions.
The Mechanism of the CDR
Unlike the heavily regulated provincial procurement platforms, the CDR operates on a self-reporting model:
- Authenticity: Manufacturers report their own prices, backed by a commitment letter confirming data accuracy.
- Verification: A state-owned operating unit conducts formal verification without interfering with the reported price level.
- Flexibility: Companies can apply to adjust prices based on clinical value, supply-demand dynamics, or competitive changes.
Overcoming International Reference Pricing (IRP) Challenges
The primary strategic goal of the CDR is to mitigate the impact of International Reference Pricing (IRP), where countries look at a drug's price in its home market to set their own limits.
- For Chinese Innovators: Companies seeking to launch in markets like Brazil have previously struggled because Brazilian regulators referenced low Chinese public insurance prices. The CDR provides authoritative proof of higher private-sector prices, facilitating fair market entry abroad.
- For Multinationals: Global firms can register private-market prices in China without fearing that these will be dragged down by public reimbursement rates, protecting their global price floors.
- Multilingual Certification: The registry provides multilingual certificates, allowing these prices to be officially recognized by international regulatory and procurement bodies.
A Broader Strategy for Innovation
The CDR is part of a larger wave of reforms aimed at making China a premier global hub for pharmaceutical innovation:
- China-ASEAN Procurement: Facilitating the entry of Chinese medicines into Southeast Asian markets.
- Confidentiality: Adoption of voluntary confidentiality pricing for the National Reimbursement Drug List (NRDL) and stricter rules for innovative drugs in commercial insurance.
- Supportive Measures: Implementation of 16 government measures to boost R&D, medical insurance access, and commercial insurance integration.
By separating public reimbursement from private market value, the National Healthcare Security Administration (NHSA) is providing a standardized and transparent platform that encourages both the globalization of Chinese medicine and the launch of new foreign drugs within China.
Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
Registered Pharmacist · AI Engineer · Director, ElendiLabs
Registered pharmacist, AI engineer, HKHAIS founder, and pharmaceutical & medical device SEO/GEO specialist.
Ask Anything
We'll follow up with you personally.
100% response rate • Reply within 7 business days
Related Articles
Approximately 5 minutes
The Regulatory Balancing Act: Cross-Border E-commerce for Unapproved Drugs in China
Cross-border retail import allows Chinese consumers to buy overseas drugs not yet approved domestically, primarily via the less-regulated **Direct Purchase Import** channel. While this improves drug **accessibility**, it poses significant **safety risks** (lack of quality assurance, no professional guidance, difficult consumer rights protection). Regulators are managing this risk through controlled **pilot programs** in cities like Beijing and Henan, aiming to shift sales towards the stricter **Bonded Warehouse Import** model.
Approximately 5 minutes
China Launches 'Beijing Model' for Legal Cross-Border E-commerce Drug Imports
In a major breakthrough, Beijing Customs pioneered the **"Beijing Model"** to create the first legal B2C channel for cross-border e-commerce drug and medical device imports into China, starting with Japanese over-the-counter medication. This aims to regularize previously illicit **"Haitao"** purchasing channels, which lacked quality control and traceability, ensuring consumers access to safe, high-quality, long-tail overseas pharmaceuticals.
Approximately 5 minutes
Navigating China NMPA Medical Device Registration: An Expert Interview with Peter of Ecomajor
An expert guide to China's NMPA medical device regulations for 2026. Peter from Ecomajor explains offline filing for Class 1, ERPS submissions for Class 2 and 3, fee structures, and how to mitigate distributor hostage risks.
Approximately 5 minutes
Eight Asian Markets, One Regulatory Map: A Medical Device Market-Access Field Guide
A systematic, jurisdiction-by-jurisdiction review of medical device regulation across China, India, Singapore, Malaysia, Indonesia, Bangladesh, and Kazakhstan, closing with a cross-cutting comparison of classification, digitalization, local-agent risk, timelines, and the universal value of CE marking and ISO 13485.